Clinical trial
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
NCT00385099 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00385099 |
|---|---|
| Title | Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome |
| Official title | A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Colon |
| Intervention type | Drug |
| Interventions | GW876008 |
| Enrollment | 10 |
| Start date | Dec 8, 2006 |
| Primary completion | Oct 15, 2007 |
| Completion | Oct 15, 2007 |
| First posted | Oct 6, 2006 |
| Last update posted | Aug 8, 2017 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: